Immunosuppression after heart and lung transplantation

被引:0
|
作者
Wendler, O [1 ]
Schafers, HJ [1 ]
机构
[1] Univ Saarlandes Kliniken, Abt Thorax & Herz Gefasschirurg, D-66421 Homburg, Germany
关键词
heart transplantation; lung transplantation; immunosuppression;
D O I
10.1007/BF03041972
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the last two decades heart and lung transplantation have evolved to an accepted treatment of endstage heart and lung failure. A differentiated immunosuppressive regimen is the long term basis of successful transplantation and must, be adopted to the individual patient. Rejection and immunosuppression with potential side effects must be balanced to achieve optimal outcome in,each patient. In the long-term follow up an efficient diagnosis and treatment of rejection probably also results in reduction of chronic organ failure and improvement of general postoperative results. In cases of vasculopathy after heart transplantation: or obliterative bronchiolitis after lung transplantation alternative; immunosuppressive drugs are options in the medical therapy. We present our postoperative management protocol after heart and lung; ; transplantation. Potential problems, new immunosuppressive options End side-effects effects of immunosuppression are discussed.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 50 条
  • [21] Immunsuppression nach Herz- und LungentransplantationImmunosuppression after heart and lung transplantation
    Olaf Wendler
    Hans -Joachim Schäfers
    Medizinische Klinik, 1997, 92 : 3 - 7
  • [22] Disturbed energy metabolism after lung and heart transplantation
    Forli, Liv
    Bollerslev, Jens
    Simonsen, Svein
    Isaksen, Gunhild A.
    Godang, Kristin
    Pripp, Are H.
    Bjortuft, Oystein
    CLINICAL TRANSPLANTATION, 2011, 25 (02) : E136 - E143
  • [23] Immunosuppression and Long-Term Survival after Heart Transplantation
    Dandel, M.
    THORACIC AND CARDIOVASCULAR SURGEON, 2009, 57 : S148 - S150
  • [24] Newer Immunosuppression and Strategies on the Horizon in Heart Transplantation
    Broch K.
    Gude E.
    Andreassen A.K.
    Gullestad L.
    Current Transplantation Reports, 2017, 4 (3) : 226 - 237
  • [25] Heart and lung transplantation in childhood and adolescence
    Kozlik-Feldmann, R.
    Griese, M.
    Netz, H.
    Birnbaum, J.
    MONATSSCHRIFT KINDERHEILKUNDE, 2012, 160 (04) : 358 - +
  • [26] Pediatric heart transplantation: immunosuppression and its complications
    Russo, LM
    Webber, SA
    CURRENT OPINION IN CARDIOLOGY, 2004, 19 (02) : 104 - 109
  • [27] First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation
    Trösch, F
    Rothenburger, M
    Schneider, M
    Welp, H
    Etz, C
    Wilhelm, MJ
    Scheld, HH
    Schmid, C
    THORACIC AND CARDIOVASCULAR SURGEON, 2004, 52 (03) : 163 - 168
  • [28] Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation
    Neurohr, Claus
    Huppmann, Patrick
    Zimmermann, Gregor
    Leuchte, Hanno
    Baumgartner, Rainer
    Hatz, Rudolf
    Frey, Lorenz
    Ueberfuhr, Peter
    Bittmann, Iris
    Behr, Juergen
    Reichart, Bruno
    TRANSPLANT INTERNATIONAL, 2009, 22 (06) : 635 - 643
  • [29] Inflammation in lung transplantation for CF - Immunosuppression and modulation of inflammation
    Mallory, GB
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2002, 23 (01) : 105 - 122
  • [30] A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation
    Goldraich, Livia A.
    Tobar Leitao, Santiago A.
    Scolari, Fernando L.
    Marcondes-Braga, Fabiana G.
    Bonatto, Marcely G.
    Munyal, Dipika
    Harrison, Jennifer
    Ribeiro, Rafaela V. P.
    Azeka, Estela
    Piardi, Diogo
    Costanzo, Maria R.
    Clausell, Nadine
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (28) : 3351 - 3384